<DOC>
	<DOCNO>NCT02002598</DOCNO>
	<brief_summary>This study design define dose-limiting toxicity determine preliminary evidence efficacy Carfilzomib ( CFZ ) combination bendamustine dexamethasone patient newly diagnose multiple myeloma ( MM ) .</brief_summary>
	<brief_title>Carfilzomib With Bendamustine Dexamethasone Multiple Myeloma</brief_title>
	<detailed_description>Multiple myeloma ( MM ) malignant plasma cell disorder result approximately 11,000 death United States year . It estimate 60,000-80,000 people currently treatment refractory relapse MM . Prognosis survival improve last 20 year , disease still universally fatal despite effort develop new effective chemotherapeutic regimen . Therefore , new regimen need developed patient prior peripheral blood stem cell transplant unable tolerate toxicity transplant .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . Life expectancy ≥ 3 month . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 4 . Adequate hepatic function . 5 . Sufficient Absolute neutrophil count ( ANC ) within 14 day prior randomization . 6 . Sufficient Hemoglobin within 14 day prior randomization ( subject may receive red blood cell [ RBC ] transfusion accordance institutional guideline ) . 7 . Sufficient platelet count 14 day prior randomization . 8 . Creatinine Clearance ≥ 30 mL/minute within 7 day prior randomization . 9 . Left Ventricular Ejection Fraction ≥ 40 % . 10 . Written inform consent accordance federal , local , institutional guideline . 11 . Females childbearing potential ( FCBP ) must agree ongoing pregnancy test practice contraception . 12 . Male subject must agree practice contraception . 13 . Patients must histologically cytologically confirm symptomatic multiple myeloma ( MM ) . Patients previously treat . 14 . Prior kyphoplasty , vertebroplasty , local radiation therapy symptomatic bone lesion ( e.g. , uncontrolled pain high risk pathologic fracture ) permit . 15 . Patients allow two cycle high dose steroid need symptomatic disease study enrollment . 1 . Patients chemotherapy Multiple Myeloma . Exception : local radiation therapy symptomatic bone lesion ( e.g. , uncontrolled pain high risk pathologic fracture ) . 2 . Patients currently receive high dose systemic steroid treatment Multiple Myeloma excess 320mg total dose dexamethasone equivalent , patient receive investigational agent within 5 halflives agent . 3 . Patients nonmeasurable Multiple Myeloma primary plasma cell leukemia . 4 . Pregnant lactating female . 5 . Major surgery within 21 day prior enrollment . 6 . Acute active infection require treatment ( systemic antibiotic , antiviral , antifungal ) within 14 day prior enrollment . 7 . Known human immunodeficiency virus ( HIV ) infection . 8 . Known active hepatitis B C infection . 9 . Unstable angina myocardial infarction within 4 month prior enrollment . 10 . Uncontrolled hypertension uncontrolled diabetes within 14 day prior enrollment . 11 . Uncontrolled , nonhematologic malignancy require active treatment . 12 . Patients know brain metastasis ( treat ) exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . 13 . Significant neuropathy within 14 day prior randomization . 14 . Known history allergy Captisol , agent study . 15 . Contraindication require concomitant drug supportive treatment , include hypersensitivity anticoagulation antiplatelet option , antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment . 16 . Subjects pleural effusion require thoracentesis ascites require paracentesis within 14 day prior enrollment . 17 . Any clinically significant medical disease condition , Investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Newly diagnose</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>myeloma</keyword>
	<keyword>bendamustine</keyword>
	<keyword>treanda</keyword>
	<keyword>carfilzomib</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>phase I</keyword>
	<keyword>phase II</keyword>
	<keyword>dose escalation</keyword>
	<keyword>transplant</keyword>
	<keyword>non-transplant , plasma cell</keyword>
</DOC>